Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 4/20 | 0.61 |
| ▸ | CRHBP | P24387 | 2/20 | 0.52 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.52 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.49 |
| ▸ | MMP8 | P22894 | 1/20 | 0.49 |
| ▸ | MMP14 | P50281 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9831290 | 0.84 | MME (0.61) | MMECRHBPCRHR2KCNQ2MAPT | |
| SCHEMBL9831283 | 0.84 | MME (0.61) | MMECRHBPCRHR2KCNQ2MAPT | |
| SCHEMBL1449796 | 0.82 | KCNQ2 (0.55) | MMECRHBPCRHR2KCNQ2MAPT | |
| SCHEMBL9828899 | 0.81 | MME (0.63) | MMECRHBPCRHR2KCNQ2MAPT | |
| SCHEMBL9828894 | 0.81 | MME (0.63) | MMECRHBPCRHR2KCNQ2MAPT | |
| SCHEMBL29359001 | 0.81 | MME (0.63) | MMEALDH1A1MMP9MMP8MMP14 | |
| SCHEMBL8344033 | 0.81 | MME (0.63) | MMEALDH1A1MMP9MMP8MMP14 | |
| SCHEMBL2328957 | 0.80 | KCNQ2 (0.49) | MMECRHBPCRHR2KCNQ2MAPT | |
| SCHEMBL2328964 | 0.80 | KCNQ2 (0.49) | MMECRHBPCRHR2KCNQ2MAPT | |
| SCHEMBL9295703 | 0.79 | MME (0.54) | MMEALDH1A1MMP9MMP8MMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | MEDA AB (SE) | 2016-06-16 | — | — | US | disclosed |
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | MEDA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20080081835-A1 | Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas | BIOLIPOX AB (SE) | 2008-04-03 | — | — | US | disclosed |
| EP-1888033-A2 | METHOD AND COMPOSITION FOR TREATING INFLAMMATORY DISORDERS | Biolipox AB (SE) | 2008-02-20 | — | — | EP | disclosed |
| EP-1742622-A1 | USE OF LTB4 INHIBITORS FOR THE TREATMENT OF B-CELL LEUKEMIAS AND LYMPHOMAS | Biolipox AB (SE) | 2007-01-17 | — | — | EP | disclosed |
| WO-2006131737-A2 | METHOD AND COMPOSITION FOR TREATING INFLAMMATORY DISORDERS | BIOLIPOX AB (SE) | 2006-12-14 | — | — | WO | disclosed |
| WO-2005107725-A1 | USE OF LTB4 INHIBITORS FOR THE TREATMENT OF B-CELL LEUKEMIAS AND LYMPHOMAS | BIOLIPOX AB (SE) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | LIPA, HRH2, HRH1 | MME 767/4885CRHBP 2490/4885CRHR2 1731/4885 |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | LIPA, HRH2, HRH1 | MME 767/4885CRHBP 2490/4885CRHR2 1731/4885 |
| US-20080081835-A1 | Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas | LTB4R, LTA4H, LTA | MME 4479/4885CRHBP 3341/4885CRHR2 4761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.